Student Research Committee, Department of Clinical Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Orthopedics, Isfahan University of Medical Sciences, Isfahan, Iran.
Complement Ther Med. 2020 Jun;51:102414. doi: 10.1016/j.ctim.2020.102414. Epub 2020 Apr 21.
We performed a meta-analysis to evaluate the efficacy of barberry (Berberis vulgaris L.) supplementation on glycemic indices in adults.
A comprehensive search was conducted in PubMed, Scopus, Cochrane Library, and ISI Web of Science from inception up to January 2020, to identify randomized controlled trials (RCTs) investigating the effect of barberry supplementation on glycemic markers including fasting blood sugar (FBS) concentrations, insulin levels, homeostatic model assessment for insulin resistance (HOMA-IR), and glycosylated hemoglobin (HbA1c) percentage. The results of this meta-analysis were reported, based on the random effects model.
In total, 7 studies, comprising 452 participants, were included in the systematic review. The meta-analysis revealed that barberry significantly reduces insulin levels (Hedges's: -0.67; 95% CI: -1.31 to -0.03, P = 0.04, I = 73.3%). However, no considerable changes was observed for FBS levels (WMD: -8.06 mg/dL; 95% CI: -20.46 to 4.33, P = 0.23, I = 96.1%), HbA1c percentage (WMD: -0.83 %; 95% CI: -2.33 to 0.67, P = 0.27, I = 88.3%), and HOMA-IR index (WMD: -0.55; 95% CI: -1.60 to 0.50, P = 0.30, I = 99.4%).
The present study suggests that although barberry supplementation significantly improves insulin levels; however, other glycemic indices might not be affected. However, more high-quality RCTs with longer duration are needed to further clarify the effects of barberry on blood glucose control, especially among patients with diabetes.
我们进行了一项荟萃分析，以评估小檗（Berberis vulgaris L.）补充剂对成年人血糖指标的疗效。
从建库至 2020 年 1 月，我们在 PubMed、Scopus、Cochrane 图书馆和 ISI Web of Science 中全面检索，以确定随机对照试验（RCT），这些试验研究了小檗补充剂对血糖标志物的影响，包括空腹血糖（FBS）浓度、胰岛素水平、胰岛素抵抗评估的稳态模型（HOMA-IR）和糖化血红蛋白（HbA1c）百分比。本荟萃分析基于随机效应模型报告结果。
共有 7 项研究，包含 452 名参与者，被纳入系统评价。荟萃分析表明，小檗显著降低胰岛素水平（Hedges's：-0.67；95% CI：-1.31 至 -0.03，P = 0.04，I = 73.3%）。然而，FBS 水平无明显变化（WMD：-8.06mg/dL；95% CI：-20.46 至 4.33，P = 0.23，I = 96.1%），HbA1c 百分比（WMD：-0.83%；95% CI：-2.33 至 0.67，P = 0.27，I = 88.3%）和 HOMA-IR 指数（WMD：-0.55；95% CI：-1.60 至 0.50，P = 0.30，I = 99.4%）。
本研究表明，虽然小檗补充剂可显著改善胰岛素水平，但其他血糖指标可能不受影响。然而，需要更多高质量、更长时间的 RCT 来进一步阐明小檗对血糖控制的影响，特别是在糖尿病患者中。
